Compare Amgen, Inc. (AMGN) vs DoorDash Inc (DASH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs DoorDash Inc — how do they compare? Amgen, Inc. trades at $413.82 (market cap $225.71B), while DoorDash Inc trades at $211.47 (market cap $90.93B). The key difference: Amgen, Inc. is far larger — about 2.5× DoorDash Inc's market cap, and Amgen, Inc. pays a 2.42% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals.
| AMGN | DASH | |
|---|---|---|
Market Cap | $225.71B | $90.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $281.74 |
52-Week Low | $271.18 | $146.60 |
Enterprise Value | $269.02B | $88.89B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $410.95, up 1.51% today, near its pivot point of $408. The stock shows bullish momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $6.29 versus $5.62 expected. Revenue reached $36.75B in 2025, with a net income margin of 22.95%. Analyst consensus is bullish with a 58.98% buy rating, though the current price exceeds the consensus target of $394.69. Technical indicators signal an overbought condition with RSI above 75.
Outlook remains positive driven by robust product growth and raised 2026 guidance, but risks include high valuation multiples, significant debt levels, and competitive pressures. The stock's proximity to resistance at $415 suggests near-term consolidation may occur, yet fundamental strength supports long-term upside potential for investors focused on biotech growth.
DoorDash (DASH) trades at $216.26, up 1.41% with strong technical momentum above key support levels. The company demonstrates robust revenue growth, with Q2 2026 revenue up 36% YoY to $4.45B, though earnings missed estimates due to higher R&D costs. Analyst sentiment remains overwhelmingly positive with 75.68% buy ratings and a $247.41 consensus price target, representing 14.4% upside potential from current levels.
DoorDash's expansion into grocery, retail, and international markets supports growth, but elevated valuation multiples (P/E 113.23) and intense competition present risks. The stock's technical strength and fundamental growth trajectory suggest continued upside, though investors should monitor execution on profitability targets and competitive pressures in the delivery space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →
